title: [Changes in blood coagulation affected by rifampicin administration].
abstract: OBJECTIVE
  To study the characteristics of influence on coagulation by rifampicin (RFP) administration.
  
  
  METHODS
  Seventy-three patients, ages between 10 and 65 years(mean age 30.3 years), with tuberculosis of neck lymphnode were treated with 2HRZS/10HRE. The prothrombin time, activity, fibrinogen, II: C, V: C, VII: C, IX: C and alanine aminotransferase concentration in each case were observed during the period of RFP administration.
  
  
  RESULTS
  The prolongation of the PT and the reduction of the PA, FIB concentration in 48 cases were observed after 5-30 days following RFP administration. These changes depended on drug dosage and duration, especially the severe influence on coagulation were detected when the RFP were reused after the ALT normalized in seventh to tenth months. The ALT was (18 +/- 12) U/L in the tenth month, but the PT was (19.2 +/- 3.9) s and the FIB was (1.8 +/- 0.5) g/L respectively.
  
  
  CONCLUSIONS
  Not only the coagulation factors II, VII, IX, X, but also I V, VI and VIII were affected by RFP. The coagulation test is more sensitive than ALT test in the evaluation of liver injury. RFP should be stopped when FIB less than 1 g/L in spite of ALT in normal range.
authors.affiliation: Department of Stomatology, PLA General Hospital, Beijing 100853.
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: R
authors.initials: R
authors.lastname: Bu
authors.forename: X
authors.initials: X
authors.lastname: Fang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000378:metabolism; D000904:Antibiotics, Antitubercular / Q000009:adverse effects* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000378:metabolism*; D002648:Child; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000293:injuries / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors; D014388:Tuberculosis, Lymph Node / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000904:Antibiotics, Antitubercular; D001779:Blood Coagulation Factors; D005340:Fibrinogen; D000410:Alanine Transaminase; D012293:Rifampin